Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 2

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Neoplasms 14Colorectal Neoplasms 9Neoplasm Metastasis 3Leukemia, Myeloid, Acute 3Sarcoma, Ewing 2Rectal Neoplasms 2Myelodysplastic Syndromes 2Liver Neoplasms 2Colonic Neoplasms 2Carcinoma, Hepatocellular 2Wilms Tumor 1Thrombocytosis 1Solid Tumor 1Small Cell Lung Carcinoma 1Rhabdomyosarcoma 1Renal Insufficiency 1Prostatic Neoplasms 1Primary Myelofibrosis 1Pretreated Metastatic Colorectal Cancer 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Neuroblastoma 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Multiple Myeloma 1Metastatic Solid Malignancies 1Lymphoma, Non-Hodgkin 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1

Interventions

Sorafenib 20Bevacizumab 7pembrolizumab 5Oxaliplatin 5Melphalan 5Leucovorin 5Irinotecan 5Nivolumab 4Ipilimumab 4Fluorouracil 4Cyclophosphamide 4Capecitabine 4fludarabine 3Sirolimus 3Radiosurgery 3Gemcitabine 3Filgrastim 3Carboplatin 3toripalimab 2spartalizumab 2regorafenib 2pazopanib 2lenvatinib 2ixabepilone 2durvalumab 2atezolizumab 2Vorinostat 2Thiotepa 2Temozolomide 2Sirtuins 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Liver Neoplasms × regorafenib × Clear all
NCT05155189 2026-01-21

A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma

Zhejiang University

Phase 1 Recruiting
72 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT03347292 2023-07-25

Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCC

Bayer

Phase 1 Completed
58 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡